[Experimental study of bone infection on WO-1 controlled-release system].
OBJECTIVE
To develop a new tissue engineering bone material which has an anti-infective function.


METHODS
Collagen loaded bio-derived bone material was made by using type-I collagen and allograft bone. WO-1 was absorbed to collagen loaded bio-derived bone, then the morphological feature of the new bone material was observed by scanning electronic microscopy. 3H-tetracycline was diluted by WO-1 solution, and was absorbed to collagen loaded bio-derived bone, then the releasing kinetics of WO-1 was detected by 3H-tetracycline in vitro. WO-1 bio-derived bone material was grafted into a culture medium with staphylococcus aureus, Escherichia coli, and pseudomonas aeruginosa to observe its bacteriostasis ability. WO-1 bio-derived bone material was grafted into radius of defected rabbits, the concentration of WO-1 was detected on the 9th, 16th, 23th, and 30th day by HLPC in blood, in bone and in muscle. The bacteriostasis ability of WO-1 loaded bio-derived bone was tested in vitro and in vivo.


RESULTS
WO-1 loaded bio-derived bone maintained natural network pore system and the surface of network pore system was coated with collagen membrane. The release of WO-1 from WO-1 loaded bio-derived bone showed bursting release on the 1st day, then showed stable release. WO-1 loaded bio-derived bone showed lasting and stable bacteriostasis to common pathogens of orthopaedic infections. The high concentration of WO-1 was observed in bone tissue and in muscle tissue at different time points and the difference among groups had no significance (P>0.05), while the concentration of WO-1 in blood was very low (P<0.05).


CONCLUSIONS
WO-1 loaded bio-derived bone has good capability of drug controlled-release and bacteriostasis.
Liang
Jun
J
Division of Stem Cell and Tissue Engineering, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu Sichuan, 610041, PR China.
Yang
Zhiming
Z
Luo
Jingcong
J
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001672:Biocompatible Materials / Q000737:chemistry / Q000494:pharmacology; D018786:Bone Substitutes / Q000737:chemistry / Q000494:pharmacology*; D016025:Bone Transplantation; D024042:Collagen Type I / Q000737:chemistry / Q000494:pharmacology*; D003692:Delayed-Action Preparations; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D011817:Rabbits; D011884:Radius / Q000293:injuries / Q000601:surgery; D023822:Tissue Engineering; D054457:Tissue Scaffolds / Q000737:chemistry; D014183:Transplantation, Heterologous
D000890:Anti-Infective Agents; D001672:Biocompatible Materials; D018786:Bone Substitutes; D024042:Collagen Type I; D003692:Delayed-Action Preparations